Cocaine Dependence Clinical Trial
Official title:
Measuring Distress Tolerance With Functional MRI
Background:
- People who are in treatment for substance abuse often feel distress during the withdrawal
period and afterward. Some individuals feel distress more acutely than others, and this
distress has been linked to poor treatment outcomes and increased risk of relapse in smokers,
alcoholics, and cocaine- and heroin-dependent individuals. More research is needed on the
effects of distress on the brain, particularly in individuals who are seeking treatment for
substance abuse. Researchers are interested in using functional magnetic resonance imaging
(fMRI) scanning to study distress tolerance in both substance users seeking treatment and
healthy non-drug-using volunteers.
Objectives:
- To use functional magnetic resonance imaging to study the effectiveness of a distress
tolerance assessment.
Eligibility:
- Individuals between 18 and 50 years of age who are either cocaine dependent or healthy
non-drug-using volunteers.
Design:
- This study involves an initial screening visit and a scanning visit, with four followup
visits.
- Participants will be screened with a medical history and physical examination, as well
as blood samples and questionnaires about mood and past and current drug use.
- Participants will have a structural MRI scan of the brain to provide a baseline reading
for comparison. Participants will then have an fMRI scanning session, which will include
both the distress tolerance assessment and relevant control tasks. Heart rate, blood
pressure, and other physical reactions will be monitored throughout the scan.
Participants will also provide blood and saliva samples to measure stress hormone
levels.
- Participants will be eligible to have followup assessments with fMRI scanning 1, 3, 6,
and 12 months after the scanning visit.
Objective: The primary objective of the current study is to implement a distress tolerance
assessment for use in fMRI to determine the neurobiological differences between individuals
with low and high distress tolerance. Additionally, other biological and physiological
indicators will be assessed, including genetic polymorphisms, salivary cortisol, galvanic
skin response, and blood pressure. The overall hypothesis is that individuals with low
distress tolerance will exhibit hyperactivation in the extended amygdala and hypoactivation
of the prefrontal cortex and anterior cingulate cortex when experiencing affective distress
and failure during a stressful task, as compared to individuals with high distress tolerance.
Study Population: The study population will consist of healthy male and female adult
volunteers (18-55 years old), as well as an otherwise healthy sample of male and female
treatment seeking substance users with cocaine users (18-55 years old) (see exclusion
criteria).
Experimental Design and Methods: After being medically cleared and giving written informed
consent, each participant will undergo a structural MRI scan of the brain, and undergo an
fMRI scanning session, which will include administration of the distress tolerance and
relevant control tasks. Physiological response to the tasks, including heart rate, blood
pressure, galvanic skin conductance, and salivary cortisol concentrations will be monitored
throughout the fMRI scan. Follow-up assessments on control and cocaine dependent participants
will occur at 1, 3, 6, and 12 months after the baseline assessment. Genetic data collected
under the aegis of protocol 10-DA-N457 will be compared with data collected under this study.
Outcome Measures: Outcome measures include distress tolerance measured as latency in seconds
to task termination on each of the distress tolerance tasks, neural indices of distress
tolerance (for all participants), and substance use treatment outcomes (for cocaine users)
including relapse to drug use, latency to first cocaine use, and number of substance use days
per week at follow-ups.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04994821 -
tDCS to Reduce Craving in Cocaine Addiction- Phase 2 Study
|
Phase 2 | |
Completed |
NCT01402492 -
Cocaine Use Reduction With Buprenorphine
|
Phase 2/Phase 3 | |
Completed |
NCT01601743 -
Exercise as a Behavioral Treatment for Cocaine Dependence
|
N/A | |
Completed |
NCT01176591 -
HBPL Study of the Impact of the NK1 Antagonist Aprepitant
|
Phase 2 | |
Completed |
NCT00880997 -
The Efficacy of Doxazosin for Cocaine Users
|
Phase 1 | |
Completed |
NCT00566969 -
Cocaine Withdrawal and Pharmacotherapy Response
|
N/A | |
Completed |
NCT00585520 -
Sex Differences in Progesterone Effects on Responses to Stress and Drug Cues
|
Phase 1 | |
Completed |
NCT00368290 -
Modafinil Treatment for Cocaine Dependence and HIV High-Risk Behavior
|
Phase 2 | |
Completed |
NCT00385801 -
Study of the Effects of Risperdal Consta on Brain Reward Circuitry Function, Craving and Cocaine Use in Active Cocaine Dependence
|
Phase 2 | |
Completed |
NCT00322309 -
Efficacy of Mirtazapine in Depressed Cocaine Dependent Subjects
|
Phase 2 | |
Completed |
NCT00167245 -
Topiramate for Alcohol and Cocaine Dependence
|
Phase 2 | |
Completed |
NCT00842517 -
Long Term Maintenance of Drug Abstinence
|
Phase 1 | |
Not yet recruiting |
NCT05974202 -
rTMS and Cognitive-behavioral Therapy for Cocaine Use Disorder
|
Phase 2 | |
Completed |
NCT04411914 -
Pharmaco-Magnetic Resonance Spectroscopy (MRS) Study of Clavulanic Acid
|
Phase 1 | |
Active, not recruiting |
NCT03266939 -
Rebalancing the Serotonergic System in Cocaine Dependence
|
Phase 1 | |
Completed |
NCT02563769 -
Clavulanic Acid (CLAV) and Cocaine Interaction Safety Study
|
Phase 1 | |
Recruiting |
NCT06159387 -
Randomized, Double-blind, Placebo-controlled Cannabis Extract x Placebo for Cocaine Addicts
|
Phase 4 | |
Terminated |
NCT02935101 -
Effects of Glucocorticoids on Craving During Detoxification Treatment of Heroin and/or Stimulants
|
Phase 2 | |
Completed |
NCT02018263 -
Validation of a Remote Wireless Sensor Network (WSN) Approach to the Individualized Detection of Cocaine Use in Humans
|
Phase 1 | |
Completed |
NCT01573273 -
Oxytocin in Cocaine Dependence
|
N/A |